Psychiatry and Clinical Psychopharmacology (PCP)

Psychiatry and Clinical Psychopharmacology (PCP), ulusal ve uluslararası çapta okurlara erişmeyi hedefler ve dünyanın her yerinden yazarların gönderdikleri makaleleri değerlendirmeye alır. Uygulamalı ve temel nörolojik bilimler ve ilgili disiplinlerde klinisyen ve bilim insanlarının orijinal çalışmalarına öncelik verir. Psychiatry and Clinical Psychopharmacology (PCP), psikiyatri, psikoloji, nöroloji, farmakoloji, moleküler biyoloji, genetik, fizyoloji, nörokimya ve ilgili bilim dallarında çalışan uzmanlar, asistan doktorlar ve bilim insanlarına yönelik yüksek bilimsel kalitede araştırmalar yayınlar.

Psychiatry and Clinical Psychopharmacology; psikiyatri ve davranış bilimi gibi önemli alanlarda klinik, deneysel ve temel bilim dallarında çalışan bilim insanlarının güncel ilgi alanlarına ilişkin konulara yer verir. PCP, temel bilimler ile klinik uygulama arasında etkin bir köprü işlevi görür. Bu dergi kapsamıyla ilgilenen tüm kişiler, ulusal ve uluslararası dernekler ve kuruluşlar herhangi bir abonelik ücreti ödemeden dergimize erişebilirler.

Psychiatry and Clinical Psychopharmacology, 1990 yılından 2016 yılına dek Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology adıyla yayınlanmıştır. Ocak 2017 tarihinden itibaren Taylor & Francis Group tarafından yine Open Access olarak “Psychiatry and Clinical Psychopharmacology” olarak yayınlanmaktadır.

ULUSLARARASI INDEKSLERE GİRMİŞ YAYINLARI

Prof. Dr. Mesut Çetin'in Kısa Yayın Listesi
1. Cetin M, Gultepe M, Ozcan A, Tarhan N, Ceylan ME, Avsar K, Cilden S, Ucuncu A, Kaya H. The role of phospholipase-A2(PLA-2) enzyme in the etiology of depression. European Neuropsychopharmacology 1992;(2):291.

2. Cetin M, Tarhan N, Ceylan ME, Burkovik Y. A double-blind comparison of the effects and side-effects of fluoxetine and placebo in the treatment of depression. Bulletin of Gulhane Military Medical Academy 1994;(36):170-173.

3. Cetin M. Efficacy and safety of sertraline in major depression. European Neuropsychopharmacology 1996;(6):18-19.

4. Cetin M. P-25 Efficacy and safety of sertraline in major depression. Topics in Catalysis 1996;(6):S18–S19. DOI: 10.1016/0924-977X(96)83837-5

5. Cetin M, Ebrinc S, Agargun MY, Yigit S. Risperidone for the treatment of monosymptomatic hypochondriacal psychosis. J Clin Psychiatry 1999;60:554.

6. Basoglu C, Cetin M, Semiz UB, Agargun MY, Ebrinc S. Premenstrual exacerbation and suicidal behavior in patients with panic disorder. Compr Psychiatry 2000;41:103-105. DOI: 10.1016/S0010-440X(00)90141-X

7. Semiz UB, Ebrinc S, Cetin M, Narin Y, Ozguven MA. Regional brain blood flow changes in the 99mTc HMPAO SPECT assessment of patients with dissociative identity disorder. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2000;10(4):176-181.

8. Sayar K, Kose O, Ebrinc S, Cetin M. Hopelessness, depression and alexithymia in young Turkish soldiers suffering from alopecia areata. Dermatology and Psychosomatics 2001;(2):12–15. DOI: 10.1159/000049631

9. Ebrinc S, Top C, Oncul O, Basoglu C, Cavuslu S, Cetin M. Serum interleukin-1 alpha and interleukin-2 levels in patients with schizophrenia. J Int Med Res 2002; 30: 314-317.

10. Basoglu C, Cetin M, Semiz UB. Hypnotizability, pain treshold and dissociative experiences in patients with borderline personality disorder and self-mutilating behavior. European Neuropsychopharmacology 2002;12:(Suppl.3)S433-S434. DOI: 10.1016/S0924-977X(02)80758-1

11. Cetin M, Basoglu C, Ebrinc S, Balibey H, Baykiz A F, Maden B. The efficacy and safety of olanzapine in combination with valproate or lithium in the treatment of mania. European Neuropsychopharmacology 2002;12:(Suppl.3):S323.

12. Cetin M, Turgay A. Antipsychotic Treatment In The Fiftieth Year Of Modern Psychopharmacology: An Update. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2002;12(4):211-226

13. Cetin M, Kose Samet, Ebrinc S, Kistak A. The assessment of the efficacy of the psychotropic drugs. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2002;12:159-164

14. Ebrinc S, Basoglu C, Cetin M, Filiz M, Sendogan N. The efficacy and safety of haloperidol and risperidone in patients with schizophrenia. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2002;12(1):6-13

15. Uzun O, Basoglu C, Cansever A, Ozsahin A, Cetin M, Ebrinc S. Body dysmorphic disorder in patients with acne. Compr Psychiatry. 2003 Sep-Oct;44(5):415-9.

16. Gultepe M, Ozcan O, Avsar K, Cetin M, Ozdemir AS, Gok M. Urine methylmalonic acid measurements for assessment of cobalamin deficiency related to neuropsychiatric disorders. Clin Biochem 2003;36:275-282.

17. Cetin M, Ebrinc S, Basoglu C, Semiz UB, Cobanoglu N, Can S, Karaduman F. Factors affecting the satisfaction of recruits with the military environment.Turk Psikiyatri Derg. 2003 Summer;14(2):125-33.

18. Cetin M, Ebrinc S, Kandilcioglu H, et al. An invesyigation of some brain regions with proton magnetic resonance spectroscopy (1H-MRS) method in patients with first episode and chronic schizophrenia. European Neuropsychopharmacology 2004;14:(Suppl.3)S239-S239.

19. Cetin M, Ebrinc S, Kandilcioglu H, Basoglu C, Basar US, Silit E, Kizilkaya E, Gunay H, Gunay H, Iyisoy M S. An investigation of some brain regions with proton magnetic resonance spectroscopy (1H-MRS) method in patients with first-episode and chronic schizophrenics. European Neuropsychopharmacology 2004;14:(Suppl.3)S239.

20. Ebrinc S, Cetin M, Oner O. Atypical antipsychotics in treatment of bipolar disorder in special populations. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2004;(14):236-250.

21. Ebrinc S, Semiz UB, Basoglu C, Cetin M, Baykiz AF, Kandilcioglu H, Balibey H. Efficacy and safety of amisulpride treatment in schizophrenia: Comparison with haloperidol Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2004;14(3):143-149.

22. Semiz UB, Turhan V, Basoglu C, Oner O, Ebrinc S, Cetin M. Leptospirosis presenting with mania and psychosis: four consecutive cases seen in a military hospital in Turkey. Int J Psychiatr Med 2005;35:299-305. DOI: 10.2190/0KUX-JE1J-HV6K-3R9J

23. Semiz UB, Basoglu C, Cetin M, Ebrinc S. Panic disorder due to ingestion of single dose ecstasy. Int J Psychiatr Clin Pract 2005; 9: 138-141. DOI: 10.1080/13651500510028968

24. Semiz U, Basoglu C, Cetin M, Ebrinc S, Uzun O, Ergun B. Body dysmorphic disorder in patients with borderline personality disorder: A preliminary study. European Neuropsychopharmacology 2005; 15:(Suppl.3)S651-S651. DOI: 10.1016/S0924-977X(05)81382-3

25. Cetin M, Kose M. Identification and posttraumatic stres disorder symptoms in rescue workers in Marmara, Turkey, earthquake. J Traumatic Stress 2005;18:485-489.

26. Cetin M, Ebrinc S, Basoglu C, Semiz UB. Efficacy and safety of long-acting injectable risperidone in schizophrenia:a 12 week open-label study in stable patients switched from typical and atypical oral antipsychotics. European Neuropsychopharmacology 2005;15:(Suppl.2)S134-S135.

27. Semi UB, Basoglu C, Ebrinc S, Ergun BM, Noyan CO, Cetin M. Body dysmorphic disorder, trauma, and dissociation in patients with borderline personality disorder: a preliminary study. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2005;15:65-70.

28. Basoglu C, Cetin M, Oner O. Comparison of rigth thalamus and temporal cortex metabolite levels of drug-naive first episode psychotic and chronic schizophrenia inpatiens. Turk Psikiyatri Dergisi 2006;17:8591.

29. Herken H, Erdal M E, Cetin M, Barlas O, Basoglu C, Uzun O, Selek S, Gokdogan T. Association between 5-HT2A receptor gene T102C and 1438G/apolymorphism and clozapine treatment response American Journal Of Medical Genetics Part B-Neuropsychiatric Genetics 2006; 141B(4):786-787.

30. Cetin M, Basoglu C, Ebrinc S. U, Semiz B, Algul A, Oguz M. Long acting risperidone in treatment of non-compliant bipolar patients. European Neuropsychopharmacology 2006;16(4):S365-S366.

31. Cetin M, Karagozoglu M. Olanzapine-induced metabolic side effects, swithing from olanzapine to ziprasidone: A pilot study. European Psychiatry 2007;22:(Suppl.1)S108-S108.

32. Algul A, Semiz U. B, Ates M. A, Cetin M, Ebrinc S, Basoglu C, Gunay H, Gunes C, Noyan C. O, Yilmaz O. Subjective sleep quality and aggression in antisocial personality disorder. European Psychiatry 2007;22:(Suppl.1)S288

33. Algul A, Semiz UB, Cetin M, Dundar O, Ates MA, Basoglu C, Ebrinc S, Gunay H, Iyisoy S. Risk factors for postpartum depression: A preliminary study. European Psychiatry 2007;22:(Suppl.1) S221-S222.

34. Cetin M, Semiz UB, Iyisoy MS, Basoglu C, Ates A, Ebrinc S. Comorbidity of adult attention deficit hyperactivity disorder and its relation to executive functions in patients with antisocial personality disorder European Psychiatry 2007;22:(Suppl.1)S270.

35. Semiz UB, Cetin M, Senol MG, Noyan O, Ates A, Basoglu C, Ebrinc S. Relationship of subjective sleep quality, daytime sleepiness, and depression to the quality of life in patients with Parkinson's disease. European Psychiatry 2007;22:(Suppl.1)S339.

36. Semiz UB, Senol MG, Basoglu C, Noyan O, Ebrinc S, Cetin M, Saracoglu M. Relationship of depressive symptoms and subjective sleep disturbances to the quality of life in patients with Parkinson's disease. Neurol Psychiatr Brain Res 2007;14:55-58.

37. Semiz UB, Basoglu C, Ebrinc S, Cetin M. Childhood trauma history and dissociative experiences among Turkish men diagnosed with antisocial personality disorder.Soc Psychiatry Psychiatr Epidemiol. 2007 Nov;42(11):865-73. Epub 2007 Aug 24. DOI: 10.1007/s00127-007-0248-2

38. Semiz UB, Cetin M, Basoglu C, Ebrinc S, Uzun O, Herken H, Balibey H, Algul A, Ates A. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia.Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1330-6. Epub 2007 Jun 12. DOI: 10.1016/j.pnpbp.2007.06.002

39. Gulsun M, Algul A, Semiz UB, Ates MA, Doruk A, Ebrinc S, Basoglu C, Cetin M. A case with euprolactinemic galactorrhea induced by escitalopram. Int J Psychiatry Med. 2007;37(3):275-8. DOI: 10.2190/PM.37.3.d

40. Semiz UB, Ates MA, Algul A, Iyisoy MS, Gunes C, Basoglu C, Cetin M. The prevalence of substance use disorder in male subjects with antisocial personality disorder. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2007;(17):162–166.

41. Dilbaz N, Karamustafaliolu O, Oral T, Onder E, Cetin M. Evaluation of compliance to treatment and factors affecting compliance for schizophrenia outpatients Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2006;16(4):223-232.

42. Ates M, Alpay A A, Gecici O, Semiz U B, Turhan V, Cetin M. Acute psychosis due to neurobrucellosis: a case report. Anadolu Psikiyatri Dergisi 2008;9:188-190.

43. Ebrinc S, Semiz UB, Basoglu C, Cetin M, Agargun MY, Algul A, Ates A. Self-mutilating behavior in patients with dissociative disorders: the role of innate hypnotic capacity. Isr J Psychiatry Relat Sci. 2008;45(1):39-48.

44. Algul A, Semiz UB, Dundar O, Ates MA, Basoglu C, Ebrinc S, Doruk A, Gecici O, Cetin M. Psychosocial and hormone related risk factors for early postnatal depressive symptoms in turkish women. Neurology, Psychiatry and Brain Research 2008:15:117-122().

45. Semiz UB, Basoglu C, Ebrinc S, Cetin M. Nightmare disorder, dream anxiety, and subjective sleep quality in patients with borderline personality disorder. Psychiatry Clin Neurosci. 2008 Feb;62(1):48-55. DOI: 10.1111/j.1440-1819.2007.01789.x

46. Semiz U, Basoglu C, Cetin M, Ebrinc S, Uzun O, Ergun B. Body dysmorphic disorder in patients with borderline personality disorder: prevalence, clinical characteristics, and role of childhood trauma. Acta Neuropsychiatrica 2008:20:33-40. DOI: 10.1111/j.1601-5215.2007.00231.x

47. Basoglu C, Semiz U, Oner O. Gunay H, Ebrinc S, Cetin M, Sildiroglu O, Algul A, Ates A, Sonmez G. A magnetic resonance spectroscopy study of antisocial behavior disorder, psychopathy and violent crime among military conscripts. Acta Neuropsychiatrica 2008:20:72-77

48. Semiz UB, Basoglu C, Oner O, Munir KM, Ates A, Algul A, Ebrinc S, Cetin M. Effects of diagnostic comorbidity and dimensional symptoms of attention-deficit-hyperactivity disorder in men with antisocial personality disorder. Aust N Z J Psychiatry. 2008 May;42(5):405-13. DOI: 10.1080/00048670801961099

49. Semiz UB, Algul A, Basoglu C, Ates MA, Ebrinc S, Cetin M, Gunes C, Gunay H. The relationship between subjective sleep quality and aggression in male subjects with antisocial personality disorder. Turk Psikiyatri Derg. 2008 Winter;19(4):373-81.

50. Ebrinc S, Algul A, Ates MA, Semiz UB, Gecici O, Basoglu C, Cetin M. Efficacy and safety of long-acting injectable risperidone during treatment of manic episode with non-compliance bipolar patients. Neurol Psychiatr Brain Res 2008:15:38-44.

51. Barlas IO, Cetin M, Erdal ME, Semiz UB, Basoglu C, Ay ME, Herken H, Uzun O. Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizoprenia patients. Am J Med Genet B Neuropsychiatr Genet 2008 Apr 30.

52. Ates MA, Algul A, Gecici O, Semiz UB, Noyan O, Basoglu C, Ebrinc S, Uzun O, Cetin M. Substance use in early adult male with first episode psychosis. Neurol Psychiatr Brain Res 2008:15:93-98.

53. Algul A, Ates MA, Gulsun M, Semiz UB, Gecici O, Noyan O, Cetin M. Epileptic seizure precipitated by using venlafaxine-extended release form: a case report. Noropsikiyatri Arsivi - Archives of Neuropsychiatry 2008;45(2):62-64(in Turkish).

54. Cetin M, Antidepressants, antipsychotics: Reliability of metaanalyses. Klinik Psikofarmakoloji Bulteni–Bulletin of Clinical Psychopharmacology, 2008:18(4):245-250(in Turkish).

55. Semiz UB, Algul, A, Cetin M. Alexithimia and aggression in patients with antisocial personality disorder. European Psychiatry 2008;23:(Suppl.2) S91.

56. Algul A, Semiz UB,Ates MA, Cetin M. Asssociation between psychosocial distress, subjective sleep qualityof life in patients with obesity: A preliminary study.European Psychiatry 2008;23: (Suppl.2)S62-S63.

57. Ebrinc S, Sahan A, Semiz UB, Cetin M. Effect of sertraline treatment on regional cerebral blood flow in OCD. European Neuropsychopharmacology 2008;18:(Suppl. 4)S62-S63.

58. Ebrinc S, Semiz UB, Oznur T, Cetin M. Neuropsychological assessment of unmadecated patients with OCD. European Neuropsychopharmacology 2008;18:(Suppl. 4)S62-S63.

59. Algul A, Ates MA, Semiz UB, Basoglu C, Ebrinc S, Gecici O, Lyisoy S, Cetin M. Relationship of substance use disorder to aggression in male subjects with antisocial personality disorder European Psychiatry 2008; 23(Suppl.2):S91

60. Algul A, Ates MA, Gulsun M, Doruk A, Semiz UB, Basoglu C, Ebrinc S, Cetin M. The relationship between self-mutilation, aggression, childhood trauma history and dissociative experiences in antisocial personality disorder. Anadolu Psikiyatri Dergisi- Anatolinan Journal of Psychiarty 2009;10:278-285(in Turkish).

61. Ates MA, Algul A, Semiz UB, Gecici O, Basoglu C, Ebrinc S, Cetin M. Clinical characteristics of self-mutilating behavior in Turkish male subjects with antisocial personality disorder. International Journal of Social Psychiatry 2009. DOI: 10.1177/0020764008099339

62. Algul A, Ayata A, Ates M A, Doruk A, Perdeci Z, Basoglu C, Semiz Ü B, Gulsun M, Ebrinc S, Cetin M, Ersanli D. The temperament and character structure of the central serous chorioretinopathy patients and correlation with anxiety and depression level. A preliminary report. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2009:19(Suppl. 1):S241-S244.

63. Algul A, Ozflahin A, Ates MA, Basoglu C, Semiz UB, Ebrinc S, Doruk A, Perdeci Z, Cetin M. The relationship between the menopausal depression and previous depressive episode, and family history of depression, and life events Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2009:19(Suppl. 1):S247-S249.

64. Noyan CO, Semiz UB, Basoglu C, Ebrinc S, Algul A, Ates MA, Yilmaz O, Cetin M. The relationship between decision-making process and features of psychopathy and temperament and character among subjects with antisocial personality disorder Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2009:19(Suppl. 1):S257-S259.

65. Berk G, Ergun BM, Narin Y, Basoglu C, Gonul AS, Ebrinc S, Cetin M, Sungur MZ. The effects of cognitive-behavioural therapy on brain regional cerebral blood flow in obsessive compulsive disorder. European Psychiatry 2009;19(Supplement 1):S312.

66. Algul A, Sen H, M Ates, Yen T, Durmaz O, Ozkan S, Basoglu C, Semiz UB, Ebrinc S, Daglı G, Cetin M. "ElektrokonvUlzif tedavide propofol ile propofol remifentanil kombinasyonun nobet suresi ve hemodinami Uzerine etkisi", Klinik Psikofarmakoloji Bulteni, Bulletin of Clinical Psychopharmacology 2009;19:24-28(in Turkish).

67. Basoglu C, M. Ates A, Algul A, Ipcioglu M, Gecici O, Yilmaz O, Semiz UB, S Ebrinc S Gulsun M, Ozcan O, Kilic S, Cetin M. Adjuvant folate with escitalopram treatment and homocystein, folate, vitamin B-12 levels in patients with major depressive disorder Klinik Psikofarmakoloji Bulteni – Bulletin of Clinical Psychopharmacology 2009;19(2):135-142.

68. Algul A, Ates MA, Semiz UB, Basoglu C, Ebrinc S, Gecici O, Gülsün M, Kardesoglu E, Cetin M. Evaluation of general psychopathology, subjective sleep quality, and health-related quality of life in patients with obesity. Int J Psychiatry Med. 2009;39(3):297-312. DOI: 10.2190/PM.39.3.f

69. Algul, A, Gulsun M, Geçici O, Ozdemir B, Basoglu C, Semiz UB, Ebrinc S, Cetin M. The relationship between alexithymia, aggression and psychopathy in young adult males with antisocial personality disorder. Noropsikiyatri Arsivi - Archives of Neuropsychiatry 2009;46:135-9 (in Turkish).

70. Cetin M, Aricioglu F, Pharmacovigilance and its significance in psychopharmacology,Klinik Psikofarmakoloji Bulteni – Bulletin of Clinical Psychopharmacology, 2009;19(4):335-339(in Turkish).

71. Cetin M, Aricioglu F. On the debate of original drug versus generic drug. Klinik Psikofarmakoloji Bulteni – Bulletin of Clinical Psychopharmacology, 2009;19(3):211-213(in Turkish).

72. Cetin M, Acikel C. In perspective of meta-analyses: Are all of the antidepressants similar? Klinik Psikofarmakoloji Bulteni – Bulletin of Clinical Psychopharmacology, 2009;19(2):87-92(in Turkish).

73. Cetin M, Kilic S. How to comprehend the recent meta-analyses conducted on typical and atypical antipsychotics?Klinik Psikofarmakoloji Bulteni –Bulletin of Clinical Psychopharmacology, 2009;19(1):1-4(in Turkish).

74. Basoglu C, Cetin M, Oner O, Ebrinc S, Semiz UB, Kandilcioglu H, Silit E, Kizilkaya E. Comparison of right thalamus and temporal cortex metabolite levels of drug-naive first-episode psychotic and chronic schizophrenia in patients. Turk Psikiyatri Derg.2006 Summer;17(2):85-91.

75. Barlas IO, Cetin M, Erdal ME, Semiz UB, Basoglu C, Ay ME, Herken H, Uzun O. Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizoprenia patients. Am J Med Genet B Neuropsychiatr Genet. 2009 Jan 5;150B(1):56-60. DOI: 10.1002/ajmg.b.30770

76. Atefl MA, Algul A, Semiz UB, Gunefl C, Cetin M.Amisulpiride Usage In Treatment-Resistant Tourette’s Syndrome: A Case Report. New/Yeni Symposium Journal 2009;47(1):16-18

77. Algul A, Sen H, Ates MA, Yen T, Durmaz O, Ozkan S, Basoglu C, U. Semiz B, Ebrinc S, Dagli G, Cetin M. Propofol versus propofolremifentanil combination anaesthesia in electroconvulsive therapy: Effects on seizure duration and hemodynamics. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2009;19(1):29-38.

78. Algul A, Gulsun M, Ates A, Ayata A, Basoglu C, Ebrinc S, Semiz UB, Ersanli D, Cetin M. Temperament and character in patients with central serous chorioretinopathy. Anatolian Journal of Clinical Investigation, 2009;(3):40-43.

79. Cetin M. Escitalopram in treatment of fibromyalgia: A pilot study International Journal Of Neuropsychopharmacology 2010;13:72.

80. Cetin M, Aricioglu F. Pharmacoeconomics and its importance in psychiatry. Klinik Psikofarmakoloji Bulteni –Bulletin of Clinical Psychopharmacology, 2010;20(1):1-4(in Turkish).

81. MacKay M, Cetin M, Baker G, Dursun S. Modulation of central nitric oxide as a therapeutic strategy for schizophrenia. Klinik Psikofarmakoloji Bulteni –Bulletin of Clinical Psychopharmacology, 2010;20(2):115-119.

82. Basoglu C, Oner O, Ates AM, Algul A, Semiz UB, Ebrinc S, Cetin M, Ozcan O, Ipcioglu OM. Association between symptom improvement and change of body mass index, lipid profile, and leptin, ghrelin, and cholecystokinin levels during 6-week olanzapine treatment in patients with first-episode psychosis. J Clin Psychopharmacol. 2010 Oct;30(5):636-8. DOI: 10.1097/JCP.0b013e3181f0580e

83. Cetin M. Escitalopram treatment of fibromyalgia: a pilot study. European Psychiatry 2010;25:(Suppl 1)S72.

84. Cetin M. A comparative study of atypical antiosychotics on sexual dysfunction. International Journal of Neuropsychopharmacology, 2010;(13):(Suppl. 1)S89.

85. Cetin M. The place of atypical antipsychotics in the treatment- resistant depressions Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2010;20(Suppl. 1):S15-S25.

86. Dursun S, Hallak J, Devarajan S, Baker G, Cetin M. High-dose antipsychotic medication; a practical pocket checklist. Klinik Psikofarmakoloji Bulteni, Bulletin of Clinical Psychopharmacology 2010;20:187-188.

87. Aricioglu F, Cetin M. Personalized drug therapy in psychiatry: Maybe a little old or a little new, but the treatment of future. Klinik Psikofarmakoloji Bulteni, Bulletin of Clinical Psychopharmacology 2010;20:269-271(in Turkish).

88. Basoglu C, Oner O, Gunes C, Semiz UB, Ates AM, Algul A, Ebrinc S, Cetin M, Ozcan O, Ipcioglu O. Plasma orexin A, ghrelin, cholecystokinin, visfatin, leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode male patients with psychosis. Int Clin Psychopharmacol. 2010 May;25(3):165-71. DOI: 10.1097/YIC.0b013e3283377850

89. Pan E, Algul A, Basoglu C, Ebrinc S, Ates M A, Semiz U B, Senol M G, Cetin M. Depression and agoraphobia in a patient with myasthenia gravis European Psychiatry 2010; 25:507.

90. Pan, E, Algul, A, Ebrinc, S, Basoglu, C, Semiz, U B, Ates, M A, Senol, M G, Cetin, M Psychiatric Mis-Diagnoses And Escitolopram Treatment of Mood And Anxiety Disorders in Myasthenia Gravis: A Case Report European Psychiatry 2010; 25:507.

91. Ates M A, Cetin M, Ebrinc S, Basoglu C, Algul A. A 39 Year Old Man With A Generalızed Rash With Bupropion Xl Administration European Psychiatry 2011;26:1225.

92. Alpay Ates M, Algul A, Semiz UB, Gecici O, Basoglu C, Ebrinc S, Cetin M. Clinical characteristics of self-mutilating behavior in Turkish male subjects with antisocial personality disorder: relationship to psychopathy. Int J Soc Psychiatry. 2011 May;57(3):237-47. Epub 2009 Nov 11. DOI: 10.1177/0020764008099339

93. Basoglu C, Oner O, Ates A, Algul A, Bez Y, Ebrinc S, Cetin M. Temperament traits and psychopathy in a group of patients with antisocial personality disorder. Compr Psychiatry. 2011 Mar 10. [Epub ahead of print] DOI: 10.1016/j.comppsych.2011.01.003

94. Karolewicz B, Cetin M, Aricioglu F. Beyond the glutamate N-methyl D-aspartate receptor in major depressive disorder: the mTOR signaling pathway. Bulletin of Clinical Psychopharmacology 2011;21:1-6. DOI: 10.5350/KPB-BCP201121101

95. Balibey H, Basoglu C, Lundgren S, Babaoglu MO, Yasar U, Herken H, Rane A, Bozkurt A, Cetin M. CYP1A2*1F polymorphism decreases clinical response to clozapine in patients with schizophrenia. Klinik Psikofarmakoloji Bülteni- Bulletin of Clinical Psychopharmacology 2011;21(2):93-9. DOI: 10.5455/bcp.20110622071701

96. Basoglu C, Oner O, Ates A, Algul A, Bez Y, Cetin M, Herken H, Erdal ME, Munir KM. Synaptosomal-associated protein 25 gene polymorphisms and antisocial personality disorder: association with temperament and psychopathy.Can J Psychiatry. 2011 Jun;56(6):341-7. DOI: 10.1177/070674371105600605

97. Cetin M. Psychotropic Drug Use in Pregnancy: An Update. Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2011;21(2):161-73. DOI: 10.5455/bcp.20110706032759

98. Cetin M, Gumru S, Feyza Aricioglu F. Nanotechnology applications in neuroscience:advances, opportunities and challenges. Bulletin of Clinical Psychopharmacology 2012;22(2):115-20. DOI: 10.5455/bcp.20120621044747

99. Cetin M, Aricioglu A, Acikel CH, Kilic S. Today's psychopharmacological treatments: results, problems, new perspectives. Bulletin of Clinical Psychopharmacology 2012;22(2):198-204. DOI: 10.5455/bcp.20120702032135

100. Dalkilic A, Cetin M. Editorial: past, present and future psychiatric trends in USA: lessons for all. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2012;22(3):205-9. DOI: 10.5455/bcp.20120912044306

101. Cetin M. Asenapine: A novel hope in the treatment of schizophrenia and manic and mixed episodes of bipolar I disorder. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2013;23(1):99-106. DOI: 10.5455/bcp.20130409040324

102. Pazvantoglu O, Algul A, Ateş M A, Sarisoy G, Ebrinc S, Basoglu C, Cetin M. Metacognitive functions in obsessive compulsive disorder in a Turkish clinical population: the relationship between symptom types and metacognition subdimensions. Bulletin of Clical Psychopharmacology 2013; 23: 65-71. DOI: 10.5455/bcp.20130127020802

103. Aydin N, Cetin M, Kurt E, Savas H, Acikel C, Kilic S, Basoglu C, Turkcapar H. A report by Turkish Association for Psychopharmacology on the psychotropic drug usage in Turkey and medical, ethical and economical consequences of current applications. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2013;23(4):390-402. DOI: 10.5455/bcp.20131230121254

104. Cetin M, Aricioglu F. Unmet needs in psychiatry and emerging novel pharmacological agents. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2013;23(3):199-204. DOI: 10.5455/bcp.20130927064824

105. Cetin M. Clozaphobia: Fear of Prescribers of Clozapine for Treatment of Schizophrenia. Klinik Psikofarmakoloji Bülteni - Bulletin of Clinical Psychopharmacology 2014;24(4):295-301. DOI: 10.5455/bcp.20141223052008

106. Cetin M, Aricioglu F. Sights For Sore Eyes and Disappointments in Psychopharmacology. Klinik Psikofarmakoloji Bülteni - Bulletin of Clinical Psychopharmacology 2014;24(2):111-4. DOI: 10.5455/bcp.20140626063115

107. Cetin M. Polypharmacy is a need in psychiatric practice. Klinik Psikofarmakoloji Bülteni - Bulletin of Clinical Psychopharmacology 2014;24:S49.

108. Cetin M. A Serious Risk: Excessive and inappropriate antipsychotic prescribing. Klinik Psikofarmakoloji Bülteni - Bulletin of Clinical Psychopharmacology 2014;24(1):1-4. DOI: 10.5455/bcp.20140314014626

109. Cetin M, Kilic S. Number needed to treat: an important measure for the correct assessment of clinical significance. Klinik Psikofarmakoloji Bülteni - Bulletin of Clinical Psychopharmacology 2015;25(1):1-3. DOI: 10.5455/bcp.20140314014626

110. Cetin M. Treatment of schizophrenia: past, present and future. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2015;25(2):95-9. DOI: 10.5455/bcp.20150630080048

111. Tutuncu R, Kilic S, Basoglu C, Ates M A, Algul A, Balibey H, Gunay H, Semiz UB, Oge C, Ebrinc S, Cetin M.The Reliability and Validity of the Turkish Version of Psychopathy Checklist-Revised (Turkish PCL–R). Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2015;25(2):118-24. DOI: 10.5455/bcp.20150310105903

112. Hizli-Sayar G, Cetin M. Over-the-counter purchase and off-label use of modafinil. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2015;25(3):312-3. DOI: 10.5455/bcp.20150720010841

113. Pan E, Ates MA, Algul A, Basoglu C, Aytekin A, Ebrinc S, Cetin M, Kose S. [0117] Schizophrenia and other psychotic disorders - Fractional anisotropic changes of the corpus callosum associated with antipsychotic treatment in first-episode antipsychotic drug-naive patients with schizophrenia. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2015;25(Ek 1):S1-S3.

114. Balibey H, Basoglu C, Ates A, Algul A, Tutuncu R, Ayata A, Yilan Y, Cetin M. [Abstract:0535] Research methods in psychiatry - Eyes tell the psychopathology: preliminary findings. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2015;25(Ek 1):S51-S2.

115. Meral G, Muftuoglu T, Basoglu C, Ates MA, Tutuncu R, Algul A, Balibey H, Ulus S, Ebrinc S, Cetin M Muftuoglu T. [Abstract:0385] Personality disorders and accentuated personality - Detection of the relationship between clinical features consisting of psychopathy levels and methylene tetrahydrofolate reductase (MTHFR) mutation among subjects with antisocial personality disorder. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2015;25(Ek 1):S154.

116. Ozmut O, Balibey H, Yilan Y, Algul A, Ebrinc S, Cetin M, Tutuncu R, Ates A, Basoglu C. [Abstract:0137] Women’s mental health - Repetitive transcranial magnetic stimulation for the treatment of depression during pregnancy and postpartum period. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2015;25(Ek 1):S203.

117. Ates A, Oner I, Tutuncu R, Basoglu C, Cetin M, Balibey H, Algul A, Ebrinc S. Relationship Between Plasma Levels of Prolactin and the Severity of Negative Symptoms in Patients with Schizophrenia. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2015;25(1):27-37. DOI: 10.5455/bcp.20141212113905

118. Hizli Sayar G, Cetin M. A Futuristic Approach to Psychiatric Diagnosis. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2015;25(4):321-5. DOI: 10.5455/bcp.20151115023922

119. Mifflin K, Benson C, Kerr B, Aricioglu F, Cetin M, Dursun S. Baker G. Involvement of Neuroactive Steroids in Pain, Depression and Anxiety. Finn DP, Leonard BE (eds): Pain in Psychiatric Disorders. Mod Trends Pharmacopsychiatry. Basel, Karger, 2015, vol 30, pp 94-102. Tutuncu RK, Selim B, Cengiz A, Mehmet AA, Ayhan B, Hakan G, Huseyin S, Umit BO, Cem ES, Cetin M. Turkish Psychopathy Checklist—Revised. 2015. DOI: 10.1159/000435935

120. Cetin M, Hizli Sayar G. Risk Evaluation and Mitigation Strategy for Clozapine. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2016;26(1):1-6. DOI: 10.5455/bcp.20160117032225

121. Hizli-Sayar G, Cetin M. Psychobiotics: the potential therapeutic promise of microbes in psychiatry. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2016;26(2):93-102. DOI: 10.5455/bcp.20160531111208

122. Sahin C, Dursun S, Cetin M, Aricioglu F. The neuroinflammation perspective of depression: reuniting the outstanding mechanisms of the pathophysiology. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2016;26(2):196-206. DOI: 10.5455/bcp.20160520092044

123. Kose S, Cetin M. ß-adrenergic Receptor Blocker Use for Traumatic Memory Reconsolidation in Posttraumatic Stress Disorder. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2016;26(3):215-22. DOI: 10.5455/bcp.20160927054221

124. Cetin M, Kose S. Klozafobik tutumlara karşı güncellenmiş klozapin ile tedavi kılavuzu. Journal of Mood Disorders (JMOOD) 2016;6(4):242-55. DOI: 10.5455/jmood.20161230061411

125. Thomas R, Cetin M, Baker GB, Dursun SM. Comment on FDA’s breakthrough therapy designation of intranasal esketamine for the treatment of major depressive disorder with imminent risk of suicide. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2016;26(4):329-31. DOI: 10.5455/bcp.20161027122045

126. Pan E, Ates MA, Algul A, Aytekin A, Basoglu C, Ebrinc S, Cetin M, Kose S. Fractional anisotropic changes of corpus callosum associated with antipsychotic treatment in first-episode antipsychotic drug-naive patients with schizophrenia. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2016;26(4):332-41. DOI: 10.5455/bcp.20160319021659

127. Aricioglu F, Sahin-Ozkartal C, Unal G, Dursun S, Cetin M, Muller N. Neuroinflammation in schizophrenia: a critical review and the future Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2016;26(4):429-37. DOI: 10.5455/bcp.20161123044657

128. Yilmaz O, Ates MA, Semiz UB, Tutuncu R, Bez Y, Algul A, Balibey H, Basoglu C, Ebrinc S, Cetin M. Childhood traumas in patients with bipolar disorder:association with alexithymia and dissociative experiences. Anatolian Journal of Psychiatry 2016; 17(3):188-195. DOI: 10.5455/apd.188358

129. Kraus M, Cetin M, Aricioglu F. The microbiota and gut-brain axis. Journal of Mood Disorders (JMOOD) 2016;6(3):172-9. DOI: 10.5455/jmood.20161004082122

130. Akin E, Cetin M, Kose S. An update on borderline personality disorder: life in the fast lane. Journal of Mood Disorders (JMOOD) 2017;7(1):65-72. DOI: 10.5455/jmood.20170308073312

131. Kose S, Cetin M. The Research Domain Criteria framework: transitioning from dimensional systems to integrating neuroscience and psychopathology. Psychiatry and Clinical Psychopharmacology 2017;27(1):1-5. DOI: 10.1080/24750573.2017.1293255

132. Kose S, Cetin M. Ketamine and electroconvulsive therapy pairing in depression and mood disorders. Psychiatry and Clinical Psychopharmacology 2017;27(2):103-105. DOI: 10.1080/24750573.2017.1332513

133. Kose S, Akin E, Cetin M. Adverse drug reactions and causality: the Turkish version of Naranjo Adverse Drug Reactions Probability Scale. Psychiatry and Clinical Psychopharmacology 2017;27(2):210-211. DOI: 10.1080/24750573.2017.1332512

134. Kose S, Cetin M. Ketamine and rapastinel: NMDA receptor modulators in the rapid treatment of obsessive-compulsive disorder. Psychiatry and Clinical Psychopharmacology 2017;27(3):213-214. DOI: 10.1080/24750573.2017.1357355

135. Kose S, Cetin M. Brexanolone: an allosteric modulator of GABA-A receptors in the rapid treatment of postpartum depression. Psychiatry and Clinical Psychopharmacology. 2017;27(4):326-328. DOI: 10.1080/24750573.2017.1380352

136. Samet Kose & Mesut Cetin (2018) Cannabis-associated psychotic symptoms and neurocognitive effects at high risk psychosis patients, Psychiatry and Clinical Psychopharmacology, 28:1, 1-3, DOI: 10.1080/24750573.2018.1403671

137. Samet Kose & Mesut Cetin (2018) Triple reuptake inhibitors (TRIs): do they promise us a rose garden?, Psychiatry and Clinical Psychopharmacology, 28:2, 119-122, DOI: 10.1080/24750573.2018.1443386

138. Samet Kose, Mesut Cetin (2018): Psychiatric pharmacogenomics in the age of neuroscience: promises and challenges, DOI: 10.1080/24750573.2018.1518191

139. Mesut Cetin & Samet Kose (2018): Serious dermatological adverse effects of vortioxetine: two cases, Psychiatry and Clinical Psychopharmacology, DOI: 10.1080/24750573.2018.1484013

140. Derya Ozsavci, Ozlem Bingol Ozakpinar, Mesut Cetin & Feyza Aricioglu(2019): Level of clinical evidence of herbal complementary therapies in psychiatric disorders, Psychiatry and Clinical Psychopharmacology, DOI: 10.1080/24750573.2019.1625587

KİTAP EDİTÖRLÜKLERİ ve KİTAP BÖLÜMLERİ

1. Mesut Çetin. Psikomatik Perspektiften Allerjik Hastalıklar ve Bronşiyal Astma. Allerjik Hastalıklar ve Bronşiyal Astma/1. Cilt. Bilmedya Grup, İstanbul, 2004 Cilt I. sayfa:291-323
2. Mesut Çetin, Bölüm 1.Psikiyatrinin Kısa Tarihi, Araştırma ve Klinik Uygulamada Biyolojik Psikiyatri,ŞİZOFRENİ. Editörler M.Emin Ceylan, Mesut Çetin, 3. baskı; Küre İletişim Grubu, İstanbul,2005, sayfa:1-65.

3. Mesut Çetin, M.Emin Ceylan, Bölüm 2.Genel Bilgiler, Araştırma ve Klinik Uygulamada Biyolojik Psikiyatri,ŞİZOFRENİ. Editörler M.Emin Ceylan, Mesut Çetin, 3. baskı; Küre İletişim Grubu, İstanbul,2005, sayfa:66-99.

4. Tarhan,N., Çetin,M.: Depresyonda Biyolojik Göstergeler,Depresyon Monografları Serisi,.(Editor) Köroğlu E. Medikomat.Hekimler Yayın Birliğli,Ankara, 1993 Vol.4,sayfa:175-200.

5. Çetin M. Tarhan N.: Depresyonun Psikoendokrinolojisi, Depresyon Monografları Serisi.,. (Editor) Köroğlu E. Medikomat.Hekimler Yayın Birliğli,Ankara, 1993 Vol.6,sayfa:253-281.

6. Klinik Psikofarmakolojide Yenilikler-I "Ulusal Sempozyum" Kitabı, Editörler: Tarhan,N, Ceylan,ME, Çetin M, İstanbul,1991.

7. Çetin,M., Evren C: Atipik Nöroleptikler. Klinik Psikofarmakolojide Yenilikler-IV "Uluslararası Katılımlı Sempozyum" Kitabı, Editörler: Çetin M, Ağargün MY, Ebrinç S. Nobel Tıp Kitabevleri,İstanbul,1998, s:92-135.

8. Çetin M. Antisosyal kişilik bozukluğunda komorbit hastalıklar, ayırıcı tanı ve idare. (Editör: Erden C.) Antisosyal Kişilik Bozukluğu , Çorlu, 2002, s:17-29.

9. Çetin M. Alerji Etyolojisinde Psikolojik Faktörlerin Rolü. (Editör: Aydilek R.): Alerjik Hastalıklar ve Bronşial Astma, İstanbul, 1998, Cilt 1, sayfa:277-300.

10. Mesut Çetin, Bölüm 1. Psikiyatrini kısa tarihi, Araştırma ve Klinik Uygulamada Biyolojik Psikiyatri,ŞİZOFRENİ. Editörler M.Emin Ceylan, Mesut Çetin, 3. baskı; Küre İletişim Grubu, İstanbul,2005, sayfa:1-83

11. Mesut Çetin, M.Emin Ceylan Bölüm 2. Genel Bilgiler, Araştırma ve Klinik Uygulamada Biyolojik Psikiyatri,ŞİZOFRENİ. Editörler M.Emin Ceylan, Mesut Çetin, 3. baskı; Küre İletişim Grubu, İstanbul,2005, sayfa:83-125

12. Mesut Çetin, M.Emin Ceylan Bölüm 3. Şizofrenide Temel Psikofarmakoloji, Araştırma ve Klinik Uygulamada Biyolojik Psikiyatri,ŞİZOFRENİ. Editörler M.Emin Ceylan, Mesut Çetin, 3. baskı; Küre İletişim Grubu, İstanbul,2005, sayfa:125-147

13. Mesut Çetin Bölüm 32. Psikiyatride hasta hakları ve etik açısından ilaç uygulaması, Araştırma ve Klinik Uygulamada Biyolojik Psikiyatri,ŞİZOFRENİ. Editörler M.Emin Ceylan, Mesut Çetin, 3. baskı; Küre İletişim Grubu, İstanbul,2005, sayfa:839-849

14. Mesut Çetin, Bölüm 33.Psikofarmakoterapinin genel ilkeleri,hasta hakları ve etik. Araştırma ve Klinik Uygulamada Biyolojik Psikiyatri,ŞİZOFRENİ. Editörler M.Emin Ceylan, Mesut Çetin, 3. baskı; Küre İletişim Grubu, İstanbul, 2005, sayfa:849-861.

15. Mesut Çetin, Bölüm 34. Antipsikotiklerin etki ve yan etkilerinin temelleri. Araştırma veKlinik Uygulamada Biyolojik Psikiyatri,ŞİZOFRENİ. Editörler M.Emin Ceylan, Mesut Çetin, 3. baskı; Küre İletişim Grubu, İstanbul,2005, sayfa:861-881

16. Mesut Çetin, M.Emin Ceylan, Bölüm 35.Tipik antipsikotikler ve antipsikotik tedavisinin klinik ilkeleri. Araştırma ve Klinik Uygulamada Biyolojik Psikiyatri,ŞİZOFRENİ. Editörler M.Emin Ceylan, Mesut Çetin, 3. baskı; Küre İletişim Grubu, İstanbul,2005, sayfa: 991-937

17. Mesut Çetin, Bölüm 36. Yeni antipsikotikler- I. Araştırma ve Klinik Uygulamada Biyolojik Psikiyatri,ŞİZOFRENİ. Editörler M.Emin Ceylan, Mesut Çetin, 3. baskı; Küre İletişim Grubu, İstanbul,2005, sayfa: 937-997.

18. Mesut Çetin, Bölüm 37. Yeni antipsikotikler- II. Araştırma ve Klinik Uygulamada Biyolojik Psikiyatri,ŞİZOFRENİ. Editörler M.Emin Ceylan, Mesut Çetin, 3. baskı; Küre İletişim Grubu, İstanbul,2005, sayfa:997-1019.

19. Mesut Çetin, Bölüm 38. Klinik uygulamada yeni antipsikotikler ve yan etkileri. Araştırma ve Klinik Uygulamada Biyolojik Psikiyatri,ŞİZOFRENİ. Editörler M.Emin Ceylan, Mesut Çetin, 3. baskı; Küre İletişim Grubu, İstanbul,2005, sayfa:1019-1067.

20. Mesut Çetin, Bölüm 39. Yeni antipsikotikler ile ilgili çeşitlikonular. Araştırma ve Klinik Uygulamada Biyolojik Psikiyatri, ŞİZOFRENİ. Editörler M.Emin Ceylan, Mesut Çetin, 3. baskı; Küre İletişim Grubu, İstanbul,2005, sayfa:1067-1117

21. Mesut Çetin, Bölüm 53. Özel durumlarda ilaç kullanımı. Araştırma ve Klinik Uygulamada Biyolojik Psikiyatri, ŞİZOFRENİ. Editörler M.Emin Ceylan, Mesut Çetin, 3. baskı; Küre İletişim Grubu, İstanbul,2005, sayfa: 1383-1403

22. Mesut Çetin, M.Emin Ceylan, Bölüm 55. Şizofrenide kullanılan testler. Araştırma ve Klinik Uygulamada Biyolojik Psikiyatri, ŞİZOFRENİ. Editörler M.Emin Ceylan, Mesut Çetin, 3. baskı; Küre İletişim Grubu, İstanbul,2005, sayfa: 1178-1271.

23. M. Emin Ceylan, Mesut Çetin, Bölüm 56. Şizofrenide kullanılan testler Araştırma ve Klinik Uygulamada Biyolojik Psikiyatri, ŞİZOFRENİ. Editörler 3. baskı; Küre İletişim Grubu, İstanbul,2005,1423-1496

24. M. Emin Ceylan, Mesut Çetin, Araştırma ve Klinik Uygulamada Biyolojik Psikiyatri, ŞİZOFRENİ. Editörler 3. baskı; Küre İletişim Grubu, İstanbul,2005

25. Mesut Çetin, Psikiyatride Etik, Klinik Psikiyatri, Kaplan Sadock's KLİNİK PSİKİYATRİ EL KİTABI H. Aydın, A.Bozkurt (çev editörleri), Güneş Kitabevi,Ankara,2005, s.615-619

26. Mesut Çetin, Servet Ebrinç, (editörler) 1.Ulusal Psikofarmakoloji Kongresi 14- 17 Aralık 2005, İstanbul ,Bildiri Özet Kitabı İstanbul,2005

27. Mesut Çetin, Servet Ebrinç, (editörler) 2.Ulusal Psikofarmakoloji Kongresi Bildiri Özet Kitabı, İstanbul 2007

ÇEVİRİLERİ
1. Mesut Çetin, (çeviri editörü) Obezitenin Bilişşsel Davranışçı Tedavisi, Küre Yayıncılık, İstanbul 2007

ÖDÜLLER
• Ebrinç S., Başoğlu C., Yılmaz V., Çetin M., Narin Y., “Majör depresyonlu hastalarda SPECT uygulaması: Geç parsiyel uyku deprivasyonu ve antidepresif ilaç tedavisinin bölgesel serebral kan perfüzyonuna etkilerinin araştırılması”. 3. Ulusal Biyolojik Psikiyatri Kongresi, 18-21 Haziran, Dedeman Otel, Kapadokya, Nevşehir, 2001, Kongre Poster Ödülü.

• Çetin M., Başoğlu C., Öner Ö., Ebrinç S., Semiz Ü.B., Kandilcioğlu H., “Kronik şizofrenili hastalarda 1H MRSI ile saptanan sağ talamik ve temporal korteks metabolik farklılıklarının psikotrop ilaç kullanmamış ilk atak psikotik bozukluklu hastalar ve sağlıklı kontrollerle karşılaştırılması” 40. Ulusal Psikiyatri Kongresi, 28 Eylül-3 Ekim 2004, Kuşadası, Türk Psikiyatri Derneği Poster Ödülü.

• Başoğlu C., Çetin M., Öner Ö., Ebrinç S., Semiz ÜB., Kandilcioğlu H, Şilit E, Kızılkaya E., “İlaç kullanmamış ve kronik psikotik hastalarda sağ talamus ve temporal korteks metabolit seviyelerinin karşılaştırılması” Türk Psikiyatri Dergisi Araştırma Ödülü, 2006.

• Pan E, Algül A, Başoğlu C, Ebrinç S, Çetin M., Aytekin A, Köse S. “Antipsikotik ilaç tedavisi almamış ilk atak şizofreni hastalarında korpus kallozumda azalmış fraksiyonel anizotropi”. Sözel Bildiri Birincilik Ödülü, 46ncı Ulusal Psikiyatri Kongresi, İzmir, 5-9 Ekim, 2010.

• Algül A, Şen H, Ateş MA, Yen T, Durmaz O, Özkan S, Başoğlu C, Semiz ÜB, Ebrinç S, Dağlı G, Çetin M. “Elektrokonvülzif tedavide propofol ile propofol remifentanil kombinasyonun nöbet süresi ve hemodinami üzerine etkisi” Poster bildiri İkincilik Ödülü, 4ncü Ulusal Psikofarmakoloji Kongresi, Antalya, 23-27 Kasım 2011.